Phase I chemoprevention study of piroxicam and α- difluoromethylornithine

Cancer Epidemiology Biomarkers and Prevention

Volumn 7, Issue 10, 1998, Pages 907-912

  Carbone, Paul P ^a,b,d   Douglas, Jeffrey A ^a,b   Larson, Paul O ^a,b   Verma, Ajit K ^a,b   Blair, Ian A ^c   Pomplun, Marcia ^a   Tutsch, Kendra D ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; EFLORNITHINE; ORNITHINE DECARBOXYLASE; PHORBOL 13 ACETATE 12 MYRISTATE; PIROXICAM; POLYAMINE; PUTRESCINE; SPERMIDINE; SPERMINE; THROMBOXANE A2;

ADULT; AGED; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DYSPNEA; ENZYME ACTIVITY; FEMALE; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN BIOPSY; TINNITUS;

ADULT; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; BIOPSY; BREAST NEOPLASMS; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; EFLORNITHINE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORNITHINE DECARBOXYLASE; PIROXICAM; POLYAMINES; PROSTATIC NEOPLASMS; SKIN NEOPLASMS;

EID: 0031661696     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Boutwell, R. K. Inhibition of chemical carcinogenesis. In: F A. Rhoads (ed.), Accomplishments in Cancer Research: 1981 Prize Year General Motors Cancer Research Foundation, pp. 225-229 Philadelphia Lippincott Company, 1982.
2. Pegg, A E, Poso, H., Shuttleworth, K., and Bennett, R. A. Effect of inhibition of polyamine synthesis on the content of decarboxylated S-adenosylmethionine. Biochem. J, 202: 519-526, 1982.
3. Verma, A. K., Duvick, L, and Ali, M. Modulation of mouse skin tumor promotion by dietary 13-cis-retinoic acid and α-difluoromethylornithine. Carcinogenesis (Lond), 7: 1019-1023, 1986.
4. Takigawa, M, Verma, A K, Simsiman, R. C., and Boutwell, R K. Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by α-difluoromethylornithine. Cancer Res, 43: 3732-3738, 1983.
5. McCann, P. P., Pegg, A. E., and Sjoerdsma, A. (eds.) Inhibition of Polyamine Metabolism. Biologic Significance and Basis for New Therapies, pp. 1-371 Orlando, FL: Academic Press, 1987.
6. Verma, A. K., Rice, H. M, and Boutwell, R. K Prostaglandins and skin tumor promotion: inhibition of tumor promoter-induced ornithine decarboxylase activity in epidermis by inhibitors of prostaglandin synthesis. Biochem. Biophys. Res. Commun, 79: 1160-1166, 1977.
7. Kelloff, G J., Malone, W. F., Boone, C W, Sigman, C. C., and Fay, J. R Progress in applied chemoprevention research Semin Oncol. 17: 438-455, 1990.
8. Reddy, B. S, Nayini, J., Tokumo, K., Rigotty, J., Zang, E., and Kelloff, G. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal anti-inflammatory drug with D,L-α-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res., 50: 2562-2568, 1990.
9. Verma, A K, Loprinzi, C. L, Boutwell, R K. and Carbone, P. P. In vitro induction of human skin ornithine decarboxylase by the tumor promoter 12-O-tetradecanoylphorbol-13-acetate. J. Natl. Cancer Inst., 75: 85-90, 1985.
10. Macek, J., and Vacha, J. Rapid and sensitive method for determination of piroxicam in human plasma by high-performance liquid chromatography J Chromatogr., 420: 445-449, 1987
11. Smithers, J. A precolumn derivatization high-performance liquid chromatographic (HPLC) procedure for the quantification of difluoromethylornithine in plasma. Pharm. Res., 5 684-686, 1988
12. Kabra, P. M, Lee, H K., Lubich, W P., and Marton, L. J. Solid-phase extraction and determination of dansyl derivatives of unconjugated and acetylated polyamines by reversed-phase liquid chromatography: improved separation systems for polyamines in cerebral spinal fluid, urine and tissue. J. Chromatogr, 380: 19-32, 1986.
13. 2 formation in the human circulation Proc. Natl. Acad. Sci. USA, 83: 5861-5865, 1986.
14. 2 in plasma and urine. Anal. Biochem, 164: 156-163, 1987
15. Love, R R., Carbone, P. P., Verma, A. K., Gilmore, D., Carey, P., Tutsch, K D., Pomplun, M, and Wilding, G Randomized phase I chemoprevention dose-seeking study of α-difluoromethylomithine. J. Natl. Cancer Inst., 85: 732-737, 1993.
16. Auvinen, M, Paasinen, A., Andersson, L. C., and Holtta, E. Ornithine decarboxylase activity is critical for cell transformation. Nature (Lond.), 360: 355-358, 1992.
17. Jaffe, B. M. Prostaglandins and cancer - an update Prostaglandins, 6: 453-461, 1974.
18. Malone, W F, Kelloff, G. J., Boone, C., and Nixon, D. W. Chemoprevention and modern cancer prevention. Prev. Med., 18: 553-561, 1989.
19. Rozhin, J, Wilson, P. S., Bull, A. W, and Nigro, N. D. Ornithine decarboxylase activity in rat and human colon. Cancer Res., 44: 3226-3230, 1984.
20. Tempero, M. A., Nishioka, K., Knott, K., and Zetterman, R. K. Chemoprevention of mouse colon tumors with difluoromethylornitine during and after carcinogen treatment. Cancer Res., 49: 5793-5797, 1989.
21. Singh, J, Kelloff, G, and Reddy, B. S. Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis. Cancer Epidemiol. Biomark. Prev., 1: 405-411, 1992.
22. Jacoby, R. F., Marshall, D. J, Newton, M A., Novakovic, K., Tutsch, K. D., Cole, C. E., Lubet, R. A., Kelloff, G. J., Verma, A. K., Moser, A. R., and Dove, W. F. Chemoprevention of spontaneous intestinal adenomas in the Apc/min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res., 56: 710-714, 1996.
23. Wargovich, M. J., Chen, C. D., Harris, C., Yang, E, and Velasco, M. Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int J. Cancer, 60: 515-519, 1995
24. Hobbs, D. C. Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex and adverse effects. Am. J Med., 81 (Suppl 5B): 22-28, 1986.